Trotman and his team, which included collaborators from Weill Cornell Medical College, Mt. Sinai School of Medicine and the Dana - Farber Cancer Institute, used RapidCaP to generate mice that developed metastatic prostate cancer with
classic hallmarks of this disease, including resistance to hormone therapy.